- List articles in this issue
Relieving the Pruritus of Atopic Dermatitis: A Meta-analysis
The goal of this study was to perform a meta-analysis on randomized controlled trials of topical therapies compared against their vehicles, and systemic therapies compared against their placebos, and to record how these therapies changed the magnitude of pruritus associated with atopic dermatitis. A systematic search of the literature was performed using Medline, Embase, and the Cochrane Controlled Clinical Trials Register, as well as follow-up references in retrieved articles. Data regarding the magnitude of the change in pruritus was extracted from eligible publications and categorized according to the type of treatment modality. Standard inverse variance fixed-effects meta-analysis was used to calculate the pooled estimates for randomized controlled trials falling under each type of treatment. Overall, the topical treatments were more successful at reducing atopic pruritus compared to the systemic treatments. Calcineurin inhibitors were the most effective antipruritic agent.
Lindsay G. Sher, Jongwha Chang, Isha B. Patel, Rajesh Balkrishnan, Alan B. Fleischer Jr
Department of Dermatology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1071, USA
Leung DY, Eichenfield LF, Boguniewicz M. Chapter 14. Atopic dermatitis (atopic eczema). In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick’s dermatology in general medicine. 7th ed. New York: McGraw-Hill; 2011.
Wolff K, Johnson RA, Suurmond D. Section 2. Eczema/Dermatitis. In: Wolff K, Johnson RA, Suurmond D, editors. Fitzpatrick’s color atlas & synopsis of clinical dermatology. 6th ed. New York: McGraw-Hill; 2011.
Ständer S, Luger TA. Itch in atopic dermatitis – pathophysiology and treatment. Acta Dermatovenerol Croat 2010; 18: 289–296.
Epstein E, Pinski JB. A blind study. Arch Dermatol 1964; 89: 548–549.
Gibbs LE. Evidence-based practice for the helping professions: A practical guide with integrated multimedia. Pacific Grove: Brooks/Cole-Thompson Learning; 2003.
Griffiths CE, Van Leent EJ, Gilbert M, Traulsen J, Cipamfylline Study Group. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol 2002; 147: 299–307.
Staab D, Kaufmann R, Bräutigam M, Wahn U, CASM981CDE04-Study Group. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents’ quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol 2005; 16: 527–533.
Langley RG Eichenfield LF, Lucky AW, Boguniewicz M, Barbier N, Cherill R. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Pediatr Dermatol 2008; 25: 301–307.
Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155–162.
Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495–504.
Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365–372.
Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatolog Treat 2010; 21: 34–44.
Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol 2009; 8: 1106–1111.
Hanifin JM, Schneider LC, Leung DYM, Ellis CN, Jaffe HS, Izu AE, et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993; 28: 189–197.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl 1980; 92: S44–S47.
Lee J, Jung E, Koh J, Kim YS, Park D. Effect of rosmarinic acid on atopic dermatitis. J Dermatol 2008; 35: 768–771.
Senapati S, Banerjee S, Gangopadhyay DN. Evening primrose oil is effective in atopic dermatitis: a randomized placebo-controlled trial. Indian J Dermatol Venereol Leprol 2008; 74: 447–452.
Williams HC. Evening primrose oil for atopic dermatitis. BMJ 2003; 327: 1358.
Leung DYM, Hanifin JM, Pariser DM, Barber KA, Langley RG, Schlievert PM, et al. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial. Br J Dermatol 2009; 161: 435–443.
Hoeger PH, Lee KH, Jautova J, Wohlrab J, Guettner A, Mizutani G, et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. Br J Dermatol 2009; 160: 415–422.
Murrell DF, Calvieri S, Ortonne JP, Ho VC, Weise-Riccardi S, Barbier N, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007; 157: 954–959.
Aschoff R, Schwanebeck U, Bräutigam M, Muerer M. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis. Exp Dermatol 2009; 18: 24–29.
Kaufmann R, Bieber T, Helgesen AL, Lasthein Andersen B, Luger T, Poulin Y, et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy 2006; 61: 375–381.
Fowler J, Johnson A, Chen M, Abrams K. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. Cutis 2007; 79: 65–72.
Baskan EB, Kacar SD, Turan A, Tunali S. A new alternative in the treatment of hand eczema: topical pimecrolimus. Turkderm deri hastaliklari ve frengi arsivi 2007; 41: 125–128.
Kaufmann R, Fölster-Holst R, Höger P, Thaçi D, Löffler H, Staab D, et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 2004; 114: 1183–1188.
Schulz P, Bunselmeyer B, Bräutigam M, Luger TA. Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol 2007; 21: 90–94.
Kapp A, Papp K, Bingham A, Fölster-Holst R, Ortonne JP, Potter PC, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277–284.
Rahman MF, Rashid MM, Sikder AU, Akhtar N, Banu LA, Wahab MA, et al. Efficacy of topical tacrolimus in atopic dermatitis. Journal of Pakistan Association of Dermatologists 2008; 18: 84–92.
Chapman MS, Schachner LA, Breneman D, Boguniewicz M, Gold MH, Shull T, et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol 2005; 53: S177–S185.
Wollenberg A, Reitamo S, Girolomoni G, Lahfa M, Ruzicka T, Healy E, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008; 63: 742–750.
Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144: 788–794.
Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998; 102: 637–644.
Schachner LA, Lamerson C, Sheehan MP, Boguniewicz M, Mosser J, Raimer S, et al. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study. Pediatrics 2005; 116: 334–342.
Hebert AA, Cook-Bolden FE, Basu S, Calvarese B, Trancik RJ, Desonide Hydrogel Study Group. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J Drugs Dermatol 2007; 6: 175–181.
Breneman D, Fleischer AB Jr, Kaplan D, Lebwohl M, Miller B, Pariser D, et al. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: A randomized evaluation versus clobetasol propionate emollient cream. J Drugs Dermatol 2005: 4: 330–336.
Abramovits A, Oquendo M. Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis. SKINmed 2010; 8: 72–79.
Lawlor F, Black AK, Greaves M. Prednicarbate 0.25% ointment in the treatment of atopic dermatitis: a vehicle-controlled double-blind study. J Dermatol Treat 1995; 6: 233–235.
Gehring W, Gloor M. Treatment of the atopic dermatitis with a water-in-oil emulsion with or without the addition of hydrocortisone – results of a controlled double-blind randomized study using clinical evaluation and bioengineering methods. Z Hautkr 1996; 71: 554–560.
Peserico A, Städtler G, Sebastian M, Suarez Fernandez R, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 2008; 158: 801–807.
Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. J Am Acad Dermatol 1994; 31: 613–616.
Lee HJ, Park CO, Lee JH, Lee KH. The antipruritic effect of topical doxepin cream in patients with atopic dermatitis. Korean J Dermatol 2006; 44: 309–314.
Stainer R, Matthews S, Arshad SH, McDonald S, Robinson J, Schapira C, et al. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2–12 years: a double-blind, randomized, placebo-controlled trial. Br J Dermatol 2004: 152: 334–341.
Patzelt-Wenczler R, Ponce-Pöschl E. Proof of efficacy of Kamillosan cream in atopic eczema. Eur J Med Res 2000; 5: 171–175.
Mayser P, Kupfer J, Nemetz D, Schäfer U, Nilles M, Hort W, et al. Treatment of head and neck dermatitis with ciclopiroxolamine cream – results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol 2006; 19: 153–158.
Patrizi A, Capitanio B, Neri I, Giacomini F, Sinagra JL, Raone B, et al. A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patients. Pediatr Allergy Immunol 2008; 19: 619–625.
Abramovits W, Boguniewicz M, Adult Atopiclair Study Group. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol 2006; 5: 236–244.
Boguniewicz M, Zeichner JA, Eichenfield LF, Hebert AA, Jarratt M, Lucky AW, et al. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. J Pediatr 2008; 152: 854–859.
Giordano-Labadie F, Cambazard F, Guillet G, Combemale P, Mengeaud V. Evaluation of a new moisturizer (Exomega milk) in children with atopic dermatitis. J Dermatolog Treat 2006; 17: 78–81.
Klövekorn W, Tepe A, Danesch U. A randomized, double-blind, vehicle-controlled, half-side comparison with a herbal ointment containing Mahonia aquifolium, Viola tricolor and Centella asiatica for the treatment of mild-to-moderate atopic dermatitis. Int J Clin Pharmacol Ther 2007; 45: 583–591.
Gueniche A, Knaudt B, Schuck E, Volz T, Bastien P, Martin R, et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 2008; 159: 1357–1363.
Leung DY, Hirsch RL, Schneider L, Moody C, Takaoka R, Meyerson LA, et al. Thymopentin therapy reduces the clinical severity of atopic dermatitis. J Allergy Clin Immunol 1990; 85: 927–933.
Stiller MJ, Shupack JL, Kenny C, Jondreau L, Cohen DE, Soter NA. A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis. J Am Acad Dermatol 1994; 30: 597–602.
Friedmann PS, Palmer R, Tan E, Ogboli M, Barclay G, Hotchkiss K, et al. A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin Exp Allergy 2007; 37: 1536–1540.
Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005; 60: 693–696.
Hannuksela M, Kalimo K, Lammintausta K, Mattila T, Turjanmaa K, Varjonen E, et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy 1993; 70: 127–133.
Cheng HM, Chiang LC, Jan YM, Chen GW, Li TC. The efficacy and safety of a Chinese herbal product (Xiao-Feng-San) for the treatment of refractory atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Int Arch Allergy Immunol 2011; 155: 141–148.
Fölster-Holst R, Müller F, Schnopp N, Abeck D, Kreiselmaier I, Lenz T, et al. Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol 2006; 155: 1256–1261.
Koch C, Dölle S, Metzger M, Rasche C, Jungclas H, Rühl R, et al. Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial. Br J Dermatol 2008; 158: 786–792.
Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004; 15: 3–27.
Schöfer H, Simonsen L. Fusidic acid in dermatology: an updated review. Eur J Dermatol 2010; 20: 6–15.
Wahlgren CF, Scheynius A, Hägermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 1990; 70: 323–329.
Akhavan A, Rudikoff D. Atopic dermatitis: systemic immunosuppressive therapy. Semin Cutan Med Surg 2008; 27: 151–155.
Berth-Jones J, Graham-Brown RA. Placebo-controlled trial of essential fatty acid supplementation in atopic dermatitis. Lancet 1993; 341: 1557–1560.
Breneman DI, Dunlap FE, Monroe EW, Schupbach, CW, Shmunes E, Phillips SB. Doxepin cream relieves eczema-associated pruritus within 15 minutes and is not accompanied by a risk of rebound upon discontinuation. J Dermatol Treat 1997; 8: 161–168.
Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44: S28–S38.
There are no related articles.
Share with your friends
Volume 92, Issue 5
View at PubMed